Advanced in Factor 7 Deficiency

Canan Albayrak

Kurupelit, TR 
Advanced in Factor 7 Deficiency
Kurupelit, TR 
OverviewLocationsClinical Research

Overview

Canan Albayrak practices in Kurupelit, Turkey. Mr. Albayrak is rated as an Advanced expert by MediFind in the treatment of Factor 7 Deficiency. His top areas of expertise are Blood Clots, Hemophilia A, Factor 7 Deficiency, Synovectomy, and Bone Marrow Transplant.

His clinical research consists of co-authoring 35 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Factor 7 Deficiency.

Gender
Male

Locations

Kurupelit, Turkey
Other Locations
Samsun, Turkey
Ondokuzmayis, Turkey

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3b, Prospective, Open-Label, Uncontrolled, Multicenter Study on Long-Term Safety and Efficacy of rVWF in Pediatric and Adult Subjects With Severe Von Willebrand Disease (VWD)
A Phase 3b, Prospective, Open-Label, Uncontrolled, Multicenter Study on Long-Term Safety and Efficacy of rVWF in Pediatric and Adult Subjects With Severe Von Willebrand Disease (VWD)
Enrollment Status: Completed
Publish Date: September 03, 2025
Intervention Type: Biological
Study Drugs: Von Willebrand Factor, Factor VIII
Study Phase: Phase 3
Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)
Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)
Enrollment Status: Completed
Publish Date: July 28, 2025
Intervention Type: Biological
Study Drugs: PEG-Factor VIII, Eloctate ITI
Study Phase: Phase 3
View 1 Less Clinical Trial

35 Total Publications

The role of leukapheresis in managing complications of hyperleukocytosis in pediatric acute leukemia.
The role of leukapheresis in managing complications of hyperleukocytosis in pediatric acute leukemia.
Journal: International journal of hematology
Published: February 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Albayrak's expertise for a condition
ConditionClose
    View All 35 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile